Press release
Primary Biliary Cholangitis Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight
Primary Biliary Cholangitis Pipeline
Explore our latest breakthroughs in Primary Biliary Cholangitis Research. Learn more about our innovative pipeline today! @ Primary Biliary Cholangitis Pipeline Outlook- https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Key Takeaways from the Primary Biliary Cholangitis Pipeline Report
• In November 2024:- GlaxoSmithKline- This is an open-label, non-comparator, global, multi-center, long-term safety study for evaluating safety and tolerability of linerixibat in participants with cholestatic pruritus in primary biliary cholangitis (PBC) who participated in a prior clinical trial with linerixibat (BAT117123 [NCT01899703], 201000 GLIMMER [NCT02966834] (group 1) or 212620 GLISTEN [NCT00210418]) (group 2). All participants will receive open-label linerixibat for the duration of the study. The study duration is expected to last until the study's end or until linerixibat can be lawfully made available to participants.
• In November 2024:- Mirum Pharmaceuticals Inc.- A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Biliary Cholangitis. The purpose of this clinical research study is to learn more about the use of the study medicine, volixibat, for the treatment of pruritus (itching) associated with Primary Biliary Cholangitis (PBC), and to assess the possible impact on the disease progression of PBC.
• In November 2024:- Intercept Pharmaceuticals- A Phase 2, Double-Blind, Randomized, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Obeticholic Acid Administered in Combination with Bezafibrate in Subjects with Primary Biliary Cholangitis Who Had an Inadequate Response or Who Were Unable to Tolerate Ursodeoxycholic Acid.
• DelveInsight's Primary Biliary Cholangitis pipeline report depicts a robust space with 18+ active players working to develop 20+ pipeline therapies for Primary Biliary Cholangitis treatment.
• The leading Primary Biliary Cholangitis Companies such as Genfit, Zydus Discovery, Ohara Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Novartis, CymaBay Therapeutics, and others.
• Promising Primary Biliary Cholangitis Therapies such as Saroglitazar Magnesium 1 mg, Seladelpar 10 mg, Obeticholic Acid Tablets, and others.
Stay informed about the cutting-edge advancements in Primary Biliary Cholangitis Treatments. Download for updates and be a part of the revolution in cancer care @ Primary Biliary Cholangitis Clinical Trials Assessment- https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Primary Biliary Cholangitis Emerging Drugs Profile
• Elafibranor: Genfit
Elafibranor is a dual agonist of the PPARα and PPARδ. Meaning the drug candidate acts simultaneously on the two nuclear receptors, which both play an important role in numerous processes involved in the development of NASH and its co-morbidities. It has shown highly significant results in its Phase 2 Study in patients with primary biliary cholangitis (PBC), while maintaining a favorable tolerability profile and lack of demonstrated safety concerns, paving the way for advancement into phase 3 clinical trial in 2020. It has recently been granted Breakthrough Therapy Designation by the FDA for the treatment of Primary Biliary Cholangitis (PBC) in adults with inadequate response to ursodeoxycholic acid (UDCA), as well as Orphan Drug Designation by the FDA and the EMA (European Medicines Agency).
• ASC42: Gannex Pharma
ASC42 is a novel non-steroidal, selective, potent FXR agonist. It has shown positive results in its Phase I Study in patients with primary biliary cholangitis with no pruritus observed and LDL-C remained within normal range at the human therapeutic dose of 15 mg. The drug is in Phase II stage of its clinical studies for Primary Biliary Cholangitis.
• OP-724: Ohara Pharmaceutical
OP-724 is a synthetic small molecule which is an inhibitor of cyclic AMP response element-binding protein (CREB)-binding protein (CBP)/β-catenin. Ohara Pharmaceutical obtained development rights for OP-724 from PRISM BioLab in 2018 . The drug is in Phase I stage of its clinical studies for Primary Biliary Cholangitis.
Learn more about Primary Biliary Cholangitis Drugs opportunities in our groundbreaking Primary Biliary Cholangitis Research and development projects @ Primary Biliary Cholangitis Unmet Needs- https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Primary Biliary Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
Primary Biliary Cholangitis Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
Discover the latest advancements in Primary Biliary Cholangitis Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Primary Biliary Cholangitis Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Scope of the Primary Biliary Cholangitis Pipeline Report
• Coverage- Global
• Primary Biliary Cholangitis Companies- Genfit, Zydus Discovery, Ohara Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Novartis, CymaBay Therapeutics, and others.
• Primary Biliary Cholangitis Therapies- Saroglitazar Magnesium 1 mg, Seladelpar 10 mg, Obeticholic Acid Tablets, and others.
• Primary Biliary Cholangitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Primary Biliary Cholangitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Primary Biliary Cholangitis Pipeline on our website @ Primary Biliary Cholangitis Drugs and Companies- https://www.delveinsight.com/sample-request/primary-biliary-cholangitis-pbc-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Table of Content
1. Introduction
2. Executive Summary
3. Primary Biliary Cholangitis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Primary Biliary Cholangitis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Elafibranor: Genfit
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ASC42: Gannex Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. OP-724: Ohara Pharmaceutical
15. Drug profiles in the detailed report…..
16. Inactive Products
17. Primary Biliary Cholangitis Key Companies
18. Primary Biliary Cholangitis Key Products
19. Primary Biliary Cholangitis- Unmet Needs
20. Primary Biliary Cholangitis- Market Drivers and Barriers
21. Primary Biliary Cholangitis- Future Perspectives and Conclusion
22. Primary Biliary Cholangitis Analyst Views
23. Primary Biliary Cholangitis Key Companies
24. Appendix
Trending Reports:
• Bacterial Skin Diseases Market: https://www.delveinsight.com/report-store/acute-bacterial-skin-and-skin-structure-infections-market
• Bcl-2 Inhibitors Market: https://www.delveinsight.com/report-store/bcl2-inhibitors-market-forecast
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Cardiac Insufficiency Market: https://www.delveinsight.com/report-store/congestive-heart-failure-market
• Central Retinal Venous Occulsion Market: https://www.delveinsight.com/report-store/retinal-vein-occlusion-market
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-cancer-market
• Chronic Hepatitis Delta Virus Market: https://www.delveinsight.com/report-store/hepatitis-d-market
• Chronic Insomnia Market: https://www.delveinsight.com/report-store/insomnia-market
• Concussions Market Size: https://www.delveinsight.com/report-store/concussions-market
• Dermal Mycosis Market: https://www.delveinsight.com/report-store/dermal-mycosis-pipeline-insight
• Epithelial Ovarian Cancer Market: https://www.delveinsight.com/report-store/ovarian-cancer-market
• Gastroenteropancreatic Neuroendocrine Tumors Market: https://www.delveinsight.com/blog/gastroenteropancreatic-neuroendocrine-tumours-market
• Gaucher Disease Market: https://www.delveinsight.com/report-store/gauchers-disease-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Goitre Market: https://www.delveinsight.com/report-store/goitre-market
• Gout Market: https://www.delveinsight.com/report-store/gout-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/audiology-devices-market
• Hemophilia B Market: https://www.delveinsight.com/report-store/hemophilia-b-market
• Hypoparathyroidism Market: https://www.delveinsight.com/report-store/hypoparathyroidism-market
• Neurofibromatosis 2 Market: https://www.delveinsight.com/report-store/neurofibromatosis-2-market
• Neuromodulation Devices Market: https://www.delveinsight.com/report-store/neuromodulation-devices-market
• Neurotrophic Keratitis Market: https://www.delveinsight.com/report-store/neurotrophic-keratitis-market
• Neurovascular Thrombectomy Devices Market: https://www.delveinsight.com/report-store/neurovascular-thrombectomy-devices-market
• Nipah Virus Infection Market: https://www.delveinsight.com/report-store/nipah-virus-niv-infection-market
• Opioid Induced Constipation Market: https://www.delveinsight.com/report-store/opioid-induced-constipation-market
• Penicillinbinding Proteins Market: https://www.delveinsight.com/report-store/penicillin-binding-proteins-market
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting/r-and-d-analysis
Case study: https://www.delveinsight.com/case-study/esmo-conference-coverage-gastrointestinal-cancers
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Primary Biliary Cholangitis Pipeline Analysis, Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Treatment Market, Therapies, MOA, ROA, Companies by DelveInsight here
News-ID: 3828704 • Views: …
More Releases from DelveInsight Business Research
Autism Spectrum Disorders Market Set for Transformative Growth as Novel Treatmen …
The Autism Spectrum Disorder (ASD) market is projected to grow steadily from 2024 to 2034, driven by rising awareness, improved diagnostic practices, and ongoing advancements in therapeutic development. Currently, major pharmaceutical companies such as Otsuka, Johnson & Johnson, and Flynn Pharma dominate the market with approved treatments including ABILIFY, RISPERDAL, and SLENYTO. Market expansion is expected as emerging therapies - developed by companies like MapLight Therapeutics, Hoffmann-La Roche, Axial Therapeutics,…
Hutchinson-Gilford Progeria Syndrome Market Poised for Strong Growth Through 203 …
DelveInsight's "Hutchinson-Gilford Progeria Syndrome (HGPS) Market Insights, Epidemiology, and Market Forecast-2032" report provides a comprehensive analysis of Hutchinson-Gilford Progeria Syndrome, including historical and projected epidemiological trends, as well as market dynamics across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
This latest healthcare forecast offers an in-depth evaluation of the HGPS landscape-covering prevalence patterns, revenue trends, and the evolving treatment ecosystem. It highlights key statistics on…
Fuchs Dystrophy Clinical Trial Assessment 2025: Over 5 Global Companies Accelera …
The Fuchs Dystrophy Pipeline Insight 2025 report delivers a comprehensive commercial and clinical evaluation of pipeline candidates, ranging from preclinical research to marketed therapies. It provides detailed drug profiles covering mechanisms of action, clinical trial updates, regulatory milestones (including NDAs where applicable), and ongoing development activities such as partnerships, funding, acquisitions, and technology platforms.
The report offers an in-depth overview of the current clinical landscape and the future growth outlook of…
Lymphangioleiomyomatosis Market Set for Significant Growth Through 2032, Reveals …
DelveInsight's "Lymphangioleiomyomatosis Market Insights, Epidemiology, and Market Forecast-2032" provides a comprehensive evaluation of Lymphangioleiomyomatosis (LAM), covering historical and projected epidemiology, market trends, and therapeutic dynamics across the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
This latest healthcare market forecast delivers an in-depth assessment of Lymphangioleiomyomatosis, including revenue trends, disease prevalence, and the evolving treatment landscape. It highlights current and future market size estimates, evaluates emerging therapies,…
More Releases for Primary
Premier Primary Care Medicine Recognized as Top-Rated Primary Care Physician in …
Premier Primary Care Medicine has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible, high-quality primary care, same-day and next-day appointments, and an approach centered on long-term patient relationships.
Marietta, GA - September 16, 2025 - Premier Primary Care Medicine [https://www.premierpcmed.com/] has been recognized as the top-rated primary care physician in Marietta, Georgia. The designation highlights the practice's commitment to accessible,…
Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd.
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as…
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and…
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit
Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy
Email primaryhealthcare@pulsusgathering.org
On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity…
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5%
Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across…
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include:
1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk…
